Sell-Side Analysts Mostly Express Undying Love For Valeant As Regulators Express DoubtsMark Melin
As the majority of sell-side analysis rushed in to defend Valeant Pharmaceuticals yesterday and early this morning, there is one point of consistency in a key component of the case that is being overlooked. The odd question of how the sales cycle worked and how a relatively small pharmacy was able to rack up such debt with Valeant has remained on the sidelines. All the positive research notes come as Valeant stock is down near 18 percent in early morning trade, and . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.